8-K: Trevi Therapeutics Provides Update on Clinical Trial Progress

Trevi Therapeutics announced updates on its clinical development programs, including the progress of its Phase 2b CORAL trial and the completion of its Human Abuse Potential study.

Summary

• Trevi Therapeutics has reached 50% enrollment in its Phase 2b CORAL trial for chronic cough in patients with idiopathic pulmonary fibrosis, triggering a sample size re-estimation.
• The sample size re-estimation outcome is expected in December 2024, which could maintain the current sample size of 160, increase it, or evaluate for futility.
• Assuming no sample size adjustments, topline results for the CORAL trial are expected in the first half of 2025.
• The company's Human Abuse Potential study has completed dosing, with topline results also expected in December 2024.
• The Phase 2a RIVER trial for refractory chronic cough has reached its planned enrollment but remains open to allow for additional enrollment to meet stratification targets.
• Topline results for the RIVER trial are now expected in the first quarter of 2025.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive, reflecting the progress in clinical trials, but tempered by the delay in the RIVER trial results and the uncertainties associated with the sample size re-estimation.

Positives

• The CORAL trial has reached a key milestone with 50% enrollment, triggering the sample size re-estimation.
• The Human Abuse Potential study has completed dosing, moving closer to data analysis.
• The RIVER trial has completed its planned enrollment, indicating progress in this study.

Negatives

• The topline results for the RIVER trial have been delayed to the first quarter of 2025.

Risks

• The sample size re-estimation for the CORAL trial could result in an increased sample size or a futility evaluation.
• Clinical trial results may not be predictive of later trials.
• There are uncertainties regarding regulatory authorities' views on the clinical trial data.
• The company faces uncertainties in estimating its cash runway and funding future operations.

Future Outlook

The company anticipates the sample size re-estimation outcome for the CORAL trial in December 2024, and topline results for the CORAL trial in the first half of 2025, assuming no sample size adjustments. Topline results for the Human Abuse Potential study are also expected in December 2024. Topline results for the RIVER trial are expected in the first quarter of 2025.

Industry Context

The announcement provides an update on Trevi Therapeutics' clinical development programs, which are focused on addressing unmet needs in chronic cough and related conditions. This is a competitive space with other companies also developing treatments for these conditions.

Comparison to Industry Standards

• The timelines for Trevi's clinical trials are generally consistent with industry standards for Phase 2 studies.
• The use of sample size re-estimation is a common practice in clinical trials to ensure adequate statistical power.
• The delay in topline results for the RIVER trial is not uncommon in clinical development, as adjustments to enrollment and data analysis can impact timelines.

Stakeholder Impact

• Shareholders will be interested in the progress of the clinical trials and the potential for future product approvals.
• Patients with chronic cough and idiopathic pulmonary fibrosis may benefit from the development of new treatments.
• Employees of Trevi Therapeutics are likely to be impacted by the progress of the clinical trials.

Next Steps

• The company will perform the sample size re-estimation for the CORAL trial.
• The company will analyze the data from the Human Abuse Potential study.
• The company will continue to enroll patients in the RIVER trial to meet stratification targets.
• The company will report topline results for the CORAL, Human Abuse Potential, and RIVER trials.

Key Dates

Keywords

clinical trials, chronic cough, idiopathic pulmonary fibrosis, sample size re-estimation, Haduvio, Trevi Therapeutics, CORAL trial, RIVER trial, Human Abuse Potential study